Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07083765 · ClinicalTrials.gov registry record · Phase 3
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
A Phase 3 study of Hypertension and Hypertension,Essential, sponsored by Ablative Solutions.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 142
- Enrollment target
- 1
- Study location
NCT07083765: Recruiting Phase 3 study of Hypertension and Hypertension,Essential, sponsored by Ablative Solutions.
NCT07083765 is a Phase 3 study of Hypertension and Hypertension,Essential that is actively recruiting participants, run by Ablative Solutions. The registered enrollment target is 142 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07083765, a Phase 3 study of Hypertension and Hypertension,Essential, is actively recruiting participants, sponsored by Ablative Solutions.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 142 participants
- Enrollment target
- 1
- Study location
Study Summary
To obtain an assessment of the efficacy and safety of renal denervation by dehydrated alcohol injection, USP administered via the Peregrine System™ Infusion Catheter in hypertensive subjects in the absence of antihypertensive medications.
Primary Outcome
Change from baseline in mean 24-hour ambulatory systolic blood pressure
Conditions Studied
Interventions
- DRUG Dehydrated Alcohol Injection, USP
- PROCEDURE Sham procedure
Study Locations (1)
Tennessee
- Tennova Turkey Creek Medical Center - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2025-09-01 |
| Est. Completion | 2027-10-31 |
| Phase | Phase 3 |
What NCT07083765 shows while recruiting
NCT07083765 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Dehydrated Alcohol Injection, USP is the first listed.
NCT07083765 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT07083765 about?
NCT07083765 is a clinical study titled "Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)". To obtain an assessment of the efficacy and safety of renal denervation by dehydrated alcohol injection, USP administered via the Peregrine System™ Infusion Catheter in hypertensive subjects in the absence of antihypertensive medications.
What is the current status of trial NCT07083765?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2025-09-01. Estimated completion is 2027-10-31.
What conditions does trial NCT07083765 study?
This clinical trial studies the following conditions: Hypertension, Hypertension,Essential.
What interventions are being tested in trial NCT07083765?
The interventions under investigation include: Dehydrated Alcohol Injection, USP (DRUG), Sham procedure (PROCEDURE).
Who is sponsoring clinical trial NCT07083765?
This trial is sponsored by Ablative Solutions, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07083765 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07083765's enrollment target sits among peer trials
142 259th of 470 higher than 212 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
-
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI